Anlon Healthcare Submits SEBI Filing for ₹1,400 Crore IPO

Anlon Healthcare, a manufacturer of pharmaceutical intermediates, has filed preliminary documents with the Securities and Exchange Board of India (SEBI) to raise funds through an initial public offering (IPO). According to the draft papers filed on October 9, the IPO will consist entirely of a fresh issue of 1.4 crore equity shares, with no offer-for-sale component.

The company plans to allocate ₹30.7 crore from the net proceeds for expanding its manufacturing facility, ₹5 crore for debt repayment, and ₹35.98 crore for working capital requirements. The remaining funds will be used for inorganic acquisitions and general corporate purposes, the company stated.

Based in Gujarat, Anlon Healthcare is promoted by Punitkumar Rasadia and Meet Atulkumar Vachhani. The promoters hold a 70.26% stake in the company, with the remaining 29.74% owned by public shareholders.

Anlon Healthcare operates a single manufacturing facility and four R&D labs. The company specializes in the production of advanced pharmaceutical intermediates and active pharmaceutical ingredients (APIs). These APIs serve as raw materials for pharmaceutical formulations, including finished dosage forms like tablets, capsules, ointments, and syrups. They are also used in nutraceuticals, personal care, and animal health products.

One of the standout products in Anlon's portfolio is loxoprofen sodium dihydrate, an API commonly used in the treatment of rheumatoid arthritis, osteoarthritis, lower back pain, frozen shoulder, neck-shoulder-arm syndrome, tooth pain, and post-surgery or injury pain.

The company's product portfolio includes 65 commercialized products, 28 products at the pilot stage, and 49 products in the R&D phase.

With this IPO, Anlon Healthcare aims to strengthen its manufacturing capabilities, repay debt, and support its working capital needs, while also pursuing opportunities for inorganic growth and fulfilling general corporate objectives.

Read more :

No related blogs available.